Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.
Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.
复制标题
DOI：
10.1007/s11912-005-0033-x
复制
发表时间：
2005-03-01
影响因子：
4.7
通讯作者：
Remick, Scot C
中科院分区：
文献类型：
--
作者：
Cooney, Matthew M;Ortiz, Jose;Remick, Scot C
正在开发新的抗癌化合物，试图利用血管内皮细胞的独特性质，血管内皮细胞提供快速分裂的肿瘤。这些血管靶向剂(VTA)或血管内皮细胞干扰剂的目的是导致肿瘤血供的迅速停止，从而导致肿瘤死于缺氧和营养缺乏。VTA分为两大类：生物疗法或小分子化合物。各种VTA处于早期临床开发阶段。这些药物已经在I期试验中显示出临床活性，并正在接受细胞毒性化疗和放射治疗的评估。
Novel anticancer compounds are being developed that attempt to exploit the unique properties of the vascular endothelium, which supplies rapidly dividing neoplasms. The goal of these vascular targeting agents (VTAs) or endothelial disrupting agents is to cause rapid shutdown of tumor blood supply with subsequent tumor death from hypoxia and nutrient deprivation. VTAs are classified into two broad categories: biologic therapies or small molecule compounds. A variety of VTAs are in early clinical development. These agents have demonstrated clinical activity in phase I trials and are being evaluated with cytotoxic chemotherapy and radiotherapy.